Login to Your Account



Pharma: Clinic Roundup


Wednesday, October 30, 2013
Merck & Co. Inc., of Whitehouse Station, N.J., presented interim data from a Phase Ib trial of MK-3475, for non-small-cell lung cancer at the World Conference on Lung Cancer in Sydney.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription